Neuralstem, Inc. 

(Public, AMEX:CUR)   Watch this stock   
Find more results for cur
Nov 17, 2009
Q3 2009 Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -325.76% -178.00%
Return on average equity - -214.86%
Employees 8 -

Address

9700 Great Seneca Highway
Rockville, MD 20850
United States - Map
+1-301-3664841 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Neuralstem, Inc. discussions

  View all discussions »

Description

Neuralstem, Inc. is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research grant and collaborative programs. The Company outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Charles River facility has the capacity to be used for cell processing under the United States Food and Drug Administration (FDA) determined good manufacturing practices (GMP) in quantities sufficient for its current pre-trial and anticipated future clinical trial needs. As of December 31, 2008, the Company had not identified any specific product.

Officers and directors

Karl Johe Ph.D.
Chairman of the Board, Chief Scientific Officer
Age: 48
Bio & Compensation - Reuters
I. Richard Garr J.D.
President, Chief Executive Officer, General Counsel, Director
Age: 56
Bio & Compensation - Reuters
John Conron
Chief Financial Officer
Age: 58
Bio & Compensation - Reuters
Scott V. Ogilvie
Director
Age: 54
Bio & Compensation - Reuters
William Oldaker
Director
Age: 67
Bio & Compensation - Reuters